CurrentHealth NetPolicy CP.PHAR.236

Darbepoetin Alfa (Aranesp)

Defines medical necessity criteria, prior-authorization requirements, approval durations, continuation criteria, exclusions, product availability, dosing, and coding guidance for darbepoetin alfa (Aranesp) across Commercial, HIM/ICHRA, and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyDarbepoetin Alfa (Aranesp)

Policy CodePolicy CP.PHAR.236

Change TypeAnnual reviews and criteria revisions (2022–2026)

Effective Date07.01.16

Next Review Date

Key ActionProvider must submit documentation (office chart notes, labs, other clinical information) supporting that member meets all approval criteria; prior authorization may be required for Retacrit or Epogen when used as redirection agents.

SourceLink

POLICY UPDATE CHANGES

2Q 2026 annual review modified current hemoglobin requirement for CKD continuation from ≤ 12 g/dL to ≤ 11.5 g/dL and added requirement that requested product is not prescribed concurrently with a HIF PH inhibitor.

2Q 2025 revised redirection language: 'member must use' Retacrit and Epogen and changed criteria to 'member must meet both of the following'; extended continuation approval duration from 6 to 12 months for Medicaid/HIM for CKD; added IL HIM bypass per IL HB 5395.

2Q 2024 added requirement for myelofibrosis pretreatment hemoglobin < 10 g/dL for initial requests and current hemoglobin ≤ 12 g/dL for continuation; for CKD added continuation current hemoglobin ≤ 12 g/dL.

2Q 2023 modified MDS continuation response assessment to occur after at least 8 weeks of therapy and added approval pathway for lower risk MDS with del(5q).

2Q 2022 removed redirection bypass for stage IV or metastatic cancer for CKD indication and updated references; template changes applied.

5Covered indications/paths (A–E)

Primary HCPCS codes listed

3Required lab thresholds

4Material changes since 2022

Coverage Summary

This policy: covered with criteria for darbepoetin alfa (Aranesp) across Commercial, HIM/ICHRA, and Medicaid lines of business and defines medical necessity, prior authorization, approval durations, continuation criteria, exclusions, and coding guidance (HCPCS J0881 and J0882).

Scope: applies to Commercial, HIM/ICHRA, and Medicaid members and lists relevant HCPCS codes for darbepoetin alfa.

High-level covered indications (sections A–E): A. Chronic kidney disease (CKD)–related anemia (dialysis and non-dialysis) with requirements for specialist involvement, iron repletion (ferritin ≥ 100 mcg/L or TSAT ≥ 20%), pretreatment hemoglobin < 10 g/dL, and absence of concurrent HIF PH inhibitor use for approval/continuation.

B. Chemotherapy-associated anemia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy (non-curative intent), with the same iron and hemoglobin thresholds (pretreatment Hgb < 10 g/dL), and continuation criteria tied to response (rise in Hgb > 1 g/dL after ≥ 8 weeks and no RBC transfusions).

C. Myelodysplastic syndrome (MDS)–associated anemia (off-label) for adults with EPO ≤ 500 mU/mL or lower-risk IPSS disease with del(5q), iron thresholds as above, pretreatment Hgb < 10 g/dL, and continuation response criteria (rise in Hgb > 1.5 g/dL after ≥ 8 weeks).

D. Myelofibrosis-associated anemia (off-label) for adults with EPO < 500 mU/mL, iron thresholds as above, pretreatment Hgb < 10 g/dL, and continuation criteria (current Hgb ≤ 12 g/dL and documented clinical response).

E. Other diagnoses/indications may be considered per off-label policies when not otherwise listed.

Step-therapy/redirection: default policy requires members to use epoetin products first — Retacrit as the initial redirection and if unable to use Retacrit then Epogen — unless contraindicated, clinically significant adverse effects occur, or product is unavailable. State-specific exceptions apply (e.g., Illinois HIM bypass per IL HB 5395 and oncology exceptions listed in Appendix D for states with redirection prohibitions).

Continuation specifics (example for CKD): member must be responding, have adequate iron stores, current hemoglobin ≤ 11.5 g/dL (updated 2Q 2026), and not be on a concurrent HIF PH inhibitor; approval durations vary by line of business.

Quick thresholds & facts

Policy numberCP.PHAR.236

Scope summaryDefines medical necessity criteria, prior-authorization requirements, continuation criteria, approval durations, exclusions, product availability, dosing, and coding guidance for darbepoetin alfa (Aranesp).

Required iron labsSerum ferritin ≥ 100 mcg/L; TSAT ≥ 20%

Pretreatment hemoglobin (initial)< 10 g/dL

Current hemoglobin — CKD continuation≤ 11.5 g/dL (updated 2Q2026)

Current hemoglobin — MDS continuation≤ 12 g/dL

Current hemoglobin — Myelofibrosis continuation≤ 12 g/dL

Response thresholds for continuation

Initial Therapy Criteria (A–E)

Continuation Therapy Criteria

Provider Actions & Billing

Prior Authorization

Prior authorization and documentation required

Provider must submit documentation (office chart notes, labs, other clinical information) supporting that member meets all approval criteria. Prior authorization may be required for Retacrit or Epogen when used as redirection agents. Affected HCPCS codes: J0881, J0882.

Documentation Required

Laboratory evidence required

Provide recent (within the last 3 months) laboratory evidence to support the request.

Serum ferritin (current within 3 months)
Transferrin saturation (TSAT) (current within 3 months)
Pretreatment hemoglobin value
Current hemoglobin value

Clinical Evidence & References

Evidence cited in the policy includes the primary reference Aranesp Prescribing Information, Amgen, December 2024 and guideline/compendium sources such as the ASH/ASCO 2019 clinical practice guideline and the NCCN Drugs & Biologics Compendium and guideline updates (2025–2026) (multiple NCCN guideline entries referenced).

The policy references guideline and compendium updates through early 2026 (NCCN compendia and specific NCCN guideline versions for MDS, myeloproliferative neoplasms, and hematopoietic growth factors are cited).

No trial-specific numeric metric cards are provided in the brief; the policy notes that metric cards are not required because the stats_bar summarizes headline counts (covered indication paths, HCPCS codes, and required lab thresholds) rather than presenting individual trial statistics.

Background

Background: Darbepoetin alfa (Aranesp) is an erythropoiesis-stimulating agent (ESA) indicated for anemia due to chronic kidney disease (CKD) — including patients on and not on dialysis — and for anemia in patients with non-myeloid malignancies when anemia is due to myelosuppressive chemotherapy (minimum planned additional 2 months of chemotherapy).

The policy also provides off-label pathways with criteria for anemia associated with myelodysplastic syndrome (MDS) and myelofibrosis, including required hematology/oncology involvement and laboratory thresholds (e.g., EPO ≤ 500 mU/mL for select patients).

This clinical policy incorporates step-therapy redirection to epoetin products: members must use Retacrit first (unless contraindicated, adverse effects, or unavailable) and if unable to use Retacrit then Epogen, with prior authorization potentially required for the redirection agents; state-specific exceptions (for example, Illinois HIM per IL HB 5395 and oncology redirection prohibitions in Appendix D) are explicitly noted.

Definitions

ESAErythropoiesis-stimulating agent

CKDChronic kidney disease

EPOErythropoietin

Revision History

05.26.2026materialLatest

2Q 2026 annual review: modified CKD continuation current hemoglobin requirement from ≤ 12 g/dL to ≤ 11.5 g/dL and added requirement that requested product is not prescribed concurrently with a HIF PH inhibitor; references reviewed and updated.

05.25.2025material

2Q 2025 annual review: revised redirection language to require 'member must use' Retacrit and Epogen and changed criteria to 'member must meet both of the following'; extended continuation approval duration from 6 to 12 months for Medicaid/HIM for CKD and added IL HIM bypass per IL HB 5395.

05.24.2024material

Policy Summary

PayerHealth Net

PolicyDarbepoetin Alfa (Aranesp)

Policy CodePolicy CP.PHAR.236

Change TypeAnnual reviews and criteria revisions (2022–2026)

Effective Date07.01.16

Next Review Date

SourceLink

On This Page

Chemotherapy: rise in Hgb > 1 g/dL after ≥ 8 weeks; MDS: rise in Hgb > 1.5 g/dL after ≥ 8 weeks

Step Therapy

Step therapy / redirection requirement

Step therapy / redirection is required in most states: member must use Retacrit first (unless contraindicated, clinically significant adverse effects, or unavailable due to shortage); if unable to use Retacrit, member must use Epogen (unless contraindicated or clinically significant adverse effects). State exceptions apply (see Appendix D). Illinois HIM exemption (IL HB 5395) effective 1/1/2026: step therapy requirements do not apply for Illinois HIM requests.

Denial Risk

Concurrent HIF-PH inhibitor use

Claims may be denied or not approved if Aranesp is prescribed concurrently with a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor.

Examples of HIF PH inhibitors: Jesduvroq, Vafseo
Concurrent use with these agents is a claim denial risk

Billing Rule

HCPCS coding guidance

HCPCS coding guidance for darbepoetin alfa: report J0881 for non‑ESRD use and J0882 for ESRD on dialysis. Codes are provided for informational purposes only; inclusion/exclusion of codes does not guarantee coverage.

J0881 — Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882 — Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)

Relevant HCPCS codes for darbepoetin alfaHCPCS

J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)

2Q 2024 annual review: added requirement for myelofibrosis that pretreatment hemoglobin < 10 g/dL for initial requests and current hemoglobin ≤ 12 g/dL for continuation; for CKD added continuation current hemoglobin ≤ 12 g/dL; references reviewed and updated.

05.23.2023material

2Q 2023 annual review: modified MDS continuation response assessment to occur after at least 8 weeks of therapy (previously 12 weeks) and added approval pathway for lower risk MDS with del(5q); references reviewed and updated.

04.27.2022non-material

2Q 2022 annual review: removed redirection bypass for stage IV or metastatic cancer for CKD indication and updated references; template changes applied.